{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:22:55Z","timestamp":1767838975824,"version":"3.49.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/hjh.0000000000000069","type":"journal-article","created":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T08:17:58Z","timestamp":1388564278000},"page":"454-463","source":"Crossref","is-referenced-by-count":52,"title":["Drug treatment of hypertension in pregnancy"],"prefix":"10.1097","volume":"32","author":[{"given":"Khalid A.J.","family":"Al Khaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginald P.","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwaleed K.","family":"Alkhaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awatif H.H.","family":"Damanhori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210208","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJM199607253350407","article-title":"Treatment of hypertension in pregnant women.","volume":"335","author":"Sibai","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-2-20210208","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/sper.2001.24903","article-title":"Antihypertensive drugs during pregnancy.","volume":"25","author":"Sibai","year":"2001","journal-title":"Semin Perinatol"},{"issue":"Suppl 1","key":"R4-2-20210208","first-page":"S1","article-title":"Hypertension Guideline Committee, and Strategic Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Scholars. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy.","volume":"30","author":"Magee","year":"2008","journal-title":"JOGC"},{"key":"R5-2-20210208","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 - Complete report.","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"R6-2-20210208","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/HYPERTENSIONAHA.106.075895","article-title":"Update on the use of antihypertensive drugs in pregnancy.","volume":"51","author":"Podynow","year":"2008","journal-title":"Hypertension"},{"key":"R7-2-20210208","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0895-7061(02)03001-7","article-title":"Hypertension guidelines: criteria that might make them more useful.","volume":"15","author":"Alderman","year":"2002","journal-title":"Am J Hypertens"},{"key":"R8-2-20210208","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/archinte.162.2.131","article-title":"Reflection on hypertension control rates. A message from the director of the National Heart, Lung and Blood Institute.","volume":"162","author":"Lenfant","year":"2002","journal-title":"Arch Intern Med"},{"key":"R11-2-20210208","first-page":"57","article-title":"South African Hypertension Guidelines 2011.","volume":"102","author":"Seedat","year":"2011","journal-title":"S Afr Med J"},{"key":"R17-2-20210208","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0929-6646(10)60120-9","article-title":"2010 Guidelines of the Taiwan Society of Cardiology for the management of hypertension.","volume":"109","author":"Chiang","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"R18-2-20210208","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4070\/kcj.2006.36.6.405","article-title":"2004 Korean hypertension treatment guidelines and its perspective.","volume":"36","author":"Park","year":"2006","journal-title":"Korean Circ J"},{"key":"R21-2-20210208","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/HJH.0b013e32832aa6d2","article-title":"Latin American Guidelines on Hypertension. Latin American Expert Group.","volume":"27","author":"Sanchez","year":"2009","journal-title":"J Hypertens"},{"key":"R23-2-20210208","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"BHS Guidelines Working Party, for the British Hypertension Society. Guidelines for management of hypertension: report of the fourth Working Party of the British Hypertension Society, - BHS IV.","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"},{"key":"R24-2-20210208","first-page":"1281","article-title":"The Task for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC).","volume":"31","year":"2013","journal-title":"J Hypertens"},{"key":"R27-2-20210208","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"Organization, International Society of Hypertension Writing Group2003 World Health Organization (WHO)International Society of Hypertension (ISH) statement on management of hypertension.","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"R29-2-20210208","first-page":"193","article-title":"Endocr P","volume":"12","year":"2006","journal-title":"ract"},{"key":"R30-2-20210208","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cjca.2011.03.015","article-title":"The 2011 Canadian Hypertension Education Program Recommendation for the Management of Hypertension: blood pressure treatment, diagnosis, assessment of risk and therapy.","volume":"27","author":"Rabi","year":"2011","journal-title":"Can J Cardiol"},{"key":"R34-2-20210208","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1136\/bmj.286.6382.1927","article-title":"Randomized controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy.","volume":"286","author":"Fidler","year":"1983","journal-title":"BMJ"},{"key":"R35-2-20210208","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0140-6736(82)92202-4","article-title":"Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children.","volume":"1","author":"Cockburn","year":"1982","journal-title":"Lancet"},{"key":"R36-2-20210208","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9378(12)90905-9","article-title":"Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension.","volume":"168","author":"Montan","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"R37-2-20210208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00002018-199207030-00007","article-title":"Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy.","volume":"7","author":"Kyle","year":"1992","journal-title":"Drug Saf"},{"key":"R38-2-20210208","first-page":"192","article-title":"The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancy complicated by hypertension.","volume":"79","author":"Puzey","year":"1991","journal-title":"S Afr Med J"},{"key":"R39-2-20210208","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/0002-9378(95)90357-7","article-title":"Calcium channel blockade (Isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study.","volume":"173","author":"Wide-Swensson","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"R40-2-20210208","first-page":"378","article-title":"Felodipine use in pregnancy. Report of three cases.","volume":"42","author":"Casele","year":"1997","journal-title":"J Reprod Med"},{"key":"R41-2-20210208","first-page":"354","article-title":"Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial.","volume":"84","author":"Jannet","year":"1994","journal-title":"Obstet Gynecol"},{"key":"R42-2-20210208","first-page":"970","article-title":"Hemodynamic changes associated with intravenous infusion of the calcium channel antagonist verapamil in the treatment of severe gestational proteinuric hypertension.","volume":"75","author":"Belfort","year":"1990","journal-title":"Obstet Gynecol"},{"key":"R43-2-20210208","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1471-0528.1993.tb15120.x","article-title":"Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks.","volume":"100","author":"Impey","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"key":"R44-2-20210208","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1067\/mob.2002.126294","article-title":"Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy.","volume":"187","author":"Brown","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R45-2-20210208","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bmj.301.6752.587","article-title":"Atenolol in essential hypertension during pregnancy.","volume":"301","author":"Butters","year":"1990","journal-title":"BMJ"},{"key":"R46-2-20210208","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0002-9149(97)00163-X","article-title":"Effect of atenolol on birth weight.","volume":"79","author":"Lip","year":"1997","journal-title":"Am J Cardiol"},{"key":"R47-2-20210208","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/bdrb.20238","article-title":"Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns.","volume":"89","author":"Nakhai-Pour","year":"2010","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"R48-2-20210208","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0301-2115(99)00113-X","article-title":"Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials.","volume":"88","author":"Magee","year":"2000","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R49-2-20210208","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/pds.2068","article-title":"Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy.","volume":"20","author":"Davis","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R51-2-20210208","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/bmj.291.6495.563","article-title":"Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa.","volume":"291","author":"Gallery","year":"1985","journal-title":"BMJ"},{"key":"R52-2-20210208","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0002-9378(84)90458-7","article-title":"Effects of diuretics on plasma volume in pregnancies with long-term hypertension.","volume":"150","author":"Sibai","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"R53-2-20210208","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/HJH.0b013e3283536319","article-title":"Hypertension in pregnancy: is it time for a new approach to treatment J H","volume":"30","author":"Moser","year":"2012","journal-title":"ypertens"},{"key":"R54-2-20210208","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1006822911586","article-title":"An overview of the reference of ACE inhibitors on fetal-placental circulation and perinatal development.","volume":"176","author":"Buttar","year":"1997","journal-title":"Mol Cell Biochem"},{"key":"R55-2-20210208","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bdra.20102","article-title":"Angiotensin II receptor antagonist treatment during pregnancy.","volume":"73","author":"Alwan","year":"2005","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R56-2-20210208","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors.","volume":"354","author":"Cooper","year":"2006","journal-title":"N Eng J Med"},{"key":"R59-2-20210208","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2006.02.015","article-title":"Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial.","volume":"128","author":"Vigil-De Gracia","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R60-2-20210208","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ultrasmedbio.2010.10.006","article-title":"Changes in fetal and maternal Doppler parameter observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized control trial.","volume":"37","author":"Baggio","year":"2011","journal-title":"Ultrasound Med Biol"},{"key":"R61-2-20210208","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/bmj.327.7421.955","article-title":"Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis.","volume":"327","author":"Magee","year":"2003","journal-title":"BMJ"},{"key":"R62-2-20210208","first-page":"e13","article-title":"The control of hypertension in pregnancy study pilot study.","volume":"770","author":"Magee","year":"2007","journal-title":"BJOG"},{"key":"R65-2-20210208","first-page":"3147","article-title":"Eur Heart","volume":"32","year":"2011","journal-title":"J"},{"key":"R66-2-20210208","first-page":"308","article-title":"Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia Am J Obstet G","volume":"159","author":"Waisman","year":"1988","journal-title":"ynecol"},{"key":"R67-2-20210208","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ajog.2004.02.050","article-title":"Symptomatic hypocalcemia after tocolytic therapy with magnesium sulfate and nifedipine.","volume":"190","author":"Koontz","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R68-2-20210208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ajog.2004.11.059","article-title":"Therapy with both magnesium sulphate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia.","volume":"193","author":"Magee","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R70-2-20210208","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2710.2008.00938.x","article-title":"Use of ACE inhibitors and ARBs in hypertensive women of childbearing age.","volume":"33","author":"Martin","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"R71-2-20210208","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1542\/peds.113.3.475","article-title":"Overweight, ethnicity, and the prevalence of hypertension in school-aged children.","volume":"113","author":"Sorof","year":"2004","journal-title":"Pediatrics"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000000069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:51:28Z","timestamp":1716378688000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201403000-00002"}},"subtitle":["a critical review of adult guideline recommendations"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0000000000000069","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}